Last reviewed · How we verify
Rotigotine, Period 2
At a glance
| Generic name | Rotigotine, Period 2 |
|---|---|
| Also known as | Neupro |
| Sponsor | UCB Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease (PHASE2)
- A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome (PHASE3)
- A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause (PHASE3)
- A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 (PHASE1)
- An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine. (PHASE1)
- Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome (PHASE4)
- Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome (PHASE2)
- Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rotigotine, Period 2 CI brief — competitive landscape report
- Rotigotine, Period 2 updates RSS · CI watch RSS
- UCB Pharma portfolio CI